GuidelineBMC endocrine disorders2025
Australasian periprocedural guideline for children and adolescents with diabetes mellitus.
Guideline in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The periprocedural period represents a critical time for children and adolescents with diabetes, during which they are at increased risk of complications. The management of diabetes in this context has become increasingly complex due to the wide range of available insulin regimens and glucose monitoring technologies. The Australasian Periprocedural Guideline for Children and Adolescents with Diabetes Mellitus has been co-developed by New Zealand Paediatric Endocrine Society, Australia and New Zealand Society for Paediatric Endocrinology and Diabetes, Society for Paediatric Anaesthesia in New Zealand and Australia, and consumer representatives. The guideline emphasises the importance of involving individuals with diabetes and their caregivers in the development of management plans, adopting a multidisciplinary approach when appropriate. It provides detailed guidance on procedure classifications, the perioperative use of existing continuous glucose monitors and insulin pumps, fasting protocols, perioperative intravenous fluid and insulin administration, and hypoglycaemia management strategies. By adhering to this guideline, healthcare providers can deliver safe, comprehensive, and patient-centred care throughout the periprocedural period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.